New York State Teachers Retirement System Has $1.31 Million Stock Position in STAAR Surgical (NASDAQ:STAA)

New York State Teachers Retirement System lowered its stake in STAAR Surgical (NASDAQ:STAA) by 7.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,016 shares of the medical instruments supplier’s stock after selling 4,038 shares during the period. New York State Teachers Retirement System owned 0.11% of STAAR Surgical worth $1,312,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Van ECK Associates Corp boosted its position in STAAR Surgical by 12.7% in the third quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after buying an additional 393 shares in the last quarter. Creative Planning boosted its position in STAAR Surgical by 8.0% in the third quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock valued at $205,000 after buying an additional 408 shares in the last quarter. LMR Partners LLP boosted its position in STAAR Surgical by 2.2% in the third quarter. LMR Partners LLP now owns 34,712 shares of the medical instruments supplier’s stock valued at $1,290,000 after buying an additional 743 shares in the last quarter. Arcadia Investment Management Corp MI acquired a new stake in STAAR Surgical in the third quarter valued at approximately $37,000. Finally, Quarry LP acquired a new stake in STAAR Surgical in the third quarter valued at approximately $50,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

Insider Activity

In related news, major shareholder Broadwood Partners, L.P. acquired 23,000 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were purchased at an average price of $24.33 per share, for a total transaction of $559,590.00. Following the completion of the acquisition, the insider now owns 10,848,631 shares of the company’s stock, valued at approximately $263,947,192.23. This trade represents a 0.21 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have purchased 402,024 shares of company stock worth $6,936,904. Company insiders own 1.00% of the company’s stock.

Analyst Upgrades and Downgrades

STAA has been the topic of a number of recent research reports. StockNews.com lowered shares of STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Canaccord Genuity Group cut their price target on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a report on Thursday, February 13th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a report on Wednesday, February 12th. Mizuho lowered shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $45.00 to $17.00 in a report on Wednesday, February 12th. Finally, Jefferies Financial Group lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $26.86.

STAAR Surgical Stock Up 0.1 %

STAA stock opened at $16.87 on Monday. The company’s fifty day simple moving average is $22.47 and its 200 day simple moving average is $28.05. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $52.68. The firm has a market cap of $831.35 million, a price-to-earnings ratio of -41.15 and a beta of 0.62.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.